anthracyclines Clinical Research Trials

Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

n the present study the neoadjuvant approach with the anti-HER2 trastuzumab and pertuzumab combined with carboplatin and paclitaxel will be used to compare the Event-Free Survival (EFS) in regimens with and without atezolizumab. Following the neoadjuvant part of the study, after surgery all patients will continue to receive trastuzumab and …

sentinel node

sentinel lymph node biopsy

cyclophosphamide

progesterone

doxorubicin

17 views
24 Jan, 2021
48 locations

RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy BREVITY

The current study (BREVITY) aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy.

adjuvant therapy

invasive breast cancer

breast cancer

cancer

28 views
24 Jan, 2021
32 locations

Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)

-transretinoic acid (ATRA) and anthracyclines without Ara-C, suggesting that avoiding Ara-C in the chemotherapy of APL reduced treatment toxicity without increasing relapses. While the relapse rate for the

cytarabine

idarubicin

remission

7 views
08 Nov, 2020
1 location

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Phase II, randomized, open-label, international, multicenter study to compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative high/intermediate risk breast cancer patients

0 views
11 Oct, 2020
28 locations

Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis

To investigate the efficacy of capecitabine combined with paclitaxel as neoadjuvant chemotherapy for gastric cancer with liver metastasis only

xeloda

liver metastasis

carcinoma

metastasis

capecitabine

16 views
08 Nov, 2020
1 location

Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction

Cardiomyopathy is a major complication of doxorubicin (DOX) chemotherapy, and 10-21% of breast cancer patients receiving DOX experience compromised cardiac function. Recent advancements have increased cancer survivorship but it remains clinically challenging to mitigate the cardiotoxic side effects. Although there are several strategies used to reduce the occurrence and severity …

2 views
31 Dec, 2020
1 location

Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)

This is a randomized, open-label, multicenter, phase III study comparing anthracyclines followed by taxane to anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in

sentinel lymph node biopsy

carcinoma

lumpectomy

carboplatin

anthracyclines

82 views
23 Jan, 2021
12 locations

Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

with very limited mature B-NHL (R1 and R2 stage I and II) of substituting anthracyclines by the rituximab window without compromising survival rates. the effectiveness (event-free survival

494 views
30 Nov, 2020
93 locations

Study for Patients With Newly Diagnosed High-risk Acute Promyelocytic Leukemia

/ATRA protocol with the addition of two doses of IDA (50% compared to standard AIDA induction) for induction because of the anticipated need of adding anthracyclines to control hyperleukocytosis and to

hysterectomy

consolidation therapy

acute promyelocytic leukemia

methotrexate

tretinoin

0 views
23 Jan, 2021
8 locations

Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)

This is a prospective, single center, randomized, open-labled stage III clinical trial comparing the efficacy and safety of anthracyclin followed by weekly paclitaxel versus dose-dense anthracyclin followed by weekly paclitaxel versus dose-dense anthracyclin followed by weekly paclitaxel combined with carboplatin for high-risk, triple-negative early breast cancer.

erbb2

platelet count

ki-67